NOTV and APLT Top After-Hours Biotech Gains; ALMS, TELA, CORT, and BRTX Also Show Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2025
0mins
Should l Buy CORT?
Source: NASDAQ.COM
Biotech Gains in After-Hours Trading: Several small-cap biotech companies saw significant stock price increases in after-hours trading, driven by earnings updates and regulatory news.
Inotiv, Inc. Performance: Inotiv, Inc. experienced a 36.61% surge to $0.94 after announcing preliminary Q4 and full-year 2025 revenue projections, recovering from a prior decline.
Applied Therapeutics and Alumis Updates: Applied Therapeutics rose 16.89% following a positive earnings report, while Alumis advanced 7.09% despite a wider Q3 net loss, supported by collaboration income.
Regulatory Developments for BioRestorative: BioRestorative Therapies gained 8.06% after announcing a meeting with the FDA to discuss a potential accelerated pathway for its treatment of chronic lumbar disc disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 35.700
Low
50.00
Averages
91.00
High
121.00
Current: 35.700
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuit Announced for Corcept Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors participating in the lawsuit may be entitled to compensation without any out-of-pocket costs, a no-risk arrangement that could attract more affected shareholders and enhance the lawsuit's impact.
- FDA Approval Risks: The lawsuit claims that Corcept misrepresented the strength of its clinical trial data supporting its New Drug Application, while the FDA had raised concerns about the adequacy of this evidence, potentially leading to significant financial losses for the company.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases.
See More
Corcept Faces Securities Fraud Class Action
- Lawsuit Background: Corcept Therapeutics is facing a securities class action lawsuit for making misleading statements between October 31, 2024, and December 30, 2025, with investors having until April 21, 2026, to apply as lead plaintiffs, highlighting significant investor concerns regarding corporate transparency.
- False Statements Allegation: The complaint alleges that the company overstated the strength of clinical trials supporting its New Drug Application (NDA), claiming “powerful support,” while the FDA raised concerns about the adequacy of clinical evidence, potentially undermining investor confidence.
- Misleading Regulatory Outlook: The company is accused of falsely conveying confidence in the regulatory prospects of relacorilant by asserting smooth communication with the FDA and no anticipated obstacles, despite the FDA's actual concerns regarding clinical evidence, which could impact future approval processes.
- Investor Loss Risks: Due to the aforementioned false statements, investors were not informed of the significant risk that Corcept's relacorilant NDA might not be approved, leading to a misrepresentation of the company's business and prospects, which could result in broader legal and financial repercussions.
See More
Class Action Lawsuit Filed Against Corcept Therapeutics
- Lawsuit Background: Rosen Law Firm has initiated a class action lawsuit on behalf of investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, alleging that the company misled investors regarding key clinical trials, resulting in shareholder losses.
- Legal Process: Investors wishing to serve as lead plaintiffs must file their motions with the court by April 21, 2026, establishing their representative status in the litigation to protect their interests effectively.
- Compensation Mechanism: Investors joining the class action will incur no upfront costs, as attorney fees will be covered through a contingency fee arrangement, thereby reducing the financial burden on affected investors and encouraging broader participation.
- Reputation Damage: The lawsuit claims that Corcept failed to disclose the inadequacy of clinical evidence when submitting its New Drug Application to the FDA, leading to investor losses upon the revelation of the truth, which may have long-term implications for the company's future financing and market trust.
See More
Corcept Therapeutics Securities Fraud Lawsuit Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by April 21, 2026, to participate in the securities fraud class action against Corcept Therapeutics (NASDAQ:CORT), which involves stock purchases made between October 31, 2024, and December 30, 2025, indicating a significant loss of investor confidence in the company's future prospects.
- FDA Rejection: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter (CRL) declining to approve its New Drug Application (NDA) for relacorilant, resulting in a 50.42% drop in stock price to $34.80 per share, highlighting the direct impact of regulatory risks on the company's market valuation.
- Clinical Development Concerns: The updated CRL revealed that the FDA had significant concerns regarding the adequacy of Corcept's clinical development program to assess relacorilant's effectiveness, suggesting that the company failed to meet regulatory expectations, which could lead to further review issues and increased investor anxiety.
- False Statements Allegations: The class action alleges that defendants made materially false and misleading statements throughout the class period, failing to disclose the FDA's concerns about the effectiveness assessment of relacorilant, leading to a misunderstanding of the company's prospects and reflecting serious deficiencies in corporate governance and transparency.
See More
Class Action Lawsuit Announced for Corcept Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, indicating potential investor losses.
- Lawsuit Background: The lawsuit alleges that Corcept made false representations regarding the efficacy of clinical trials supporting its New Drug Application, leading investors to be unaware of the significant risks associated with FDA approval.
- Compensation Mechanism: Investors joining the class action can receive compensation without any out-of-pocket fees, facilitated through a contingency fee arrangement, thus alleviating financial burdens on investors.
- Legal Counsel Recommendation: Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record to ensure that investors' rights are effectively protected in the class action process.
See More
Corcept Therapeutics Faces Class Action Lawsuit Over Misleading FDA Claims
- Lawsuit Background: Hagens Berman has filed a class action lawsuit against Corcept Therapeutics and its executives, alleging that misleading statements made between October 31, 2024, and December 30, 2025, resulted in significant investor losses.
- Concealed FDA Warnings: The lawsuit claims that Corcept misled the market by asserting its lead product was nearing approval, despite receiving multiple warnings from the FDA about inadequate clinical data prior to its NDA submission, leading to investor misconceptions about the company's prospects.
- Stock Price Plummet: On December 31, 2025, Corcept's stock price collapsed from $70.20 to $34.80 following the announcement of a Complete Response Letter from the FDA, erasing over $3.6 billion in market value, reflecting extreme market disappointment in the company's future.
- Investor Action Call: Hagens Berman urges investors who purchased Corcept stock during the class period to contact the firm by April 21, 2026, to discuss their rights and potentially serve as lead plaintiffs in the lawsuit, emphasizing the importance of protecting their interests.
See More
Class Action Lawsuit Announced for Corcept Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors participating in the lawsuit may be entitled to compensation without any out-of-pocket costs, a no-risk arrangement that could attract more affected shareholders and enhance the lawsuit's impact.
- FDA Approval Risks: The lawsuit claims that Corcept misrepresented the strength of its clinical trial data supporting its New Drug Application, while the FDA had raised concerns about the adequacy of this evidence, potentially leading to significant financial losses for the company.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases.
See More
Corcept Faces Securities Fraud Class Action
- Lawsuit Background: Corcept Therapeutics is facing a securities class action lawsuit for making misleading statements between October 31, 2024, and December 30, 2025, with investors having until April 21, 2026, to apply as lead plaintiffs, highlighting significant investor concerns regarding corporate transparency.
- False Statements Allegation: The complaint alleges that the company overstated the strength of clinical trials supporting its New Drug Application (NDA), claiming “powerful support,” while the FDA raised concerns about the adequacy of clinical evidence, potentially undermining investor confidence.
- Misleading Regulatory Outlook: The company is accused of falsely conveying confidence in the regulatory prospects of relacorilant by asserting smooth communication with the FDA and no anticipated obstacles, despite the FDA's actual concerns regarding clinical evidence, which could impact future approval processes.
- Investor Loss Risks: Due to the aforementioned false statements, investors were not informed of the significant risk that Corcept's relacorilant NDA might not be approved, leading to a misrepresentation of the company's business and prospects, which could result in broader legal and financial repercussions.
See More
Class Action Lawsuit Filed Against Corcept Therapeutics
- Lawsuit Background: Rosen Law Firm has initiated a class action lawsuit on behalf of investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, alleging that the company misled investors regarding key clinical trials, resulting in shareholder losses.
- Legal Process: Investors wishing to serve as lead plaintiffs must file their motions with the court by April 21, 2026, establishing their representative status in the litigation to protect their interests effectively.
- Compensation Mechanism: Investors joining the class action will incur no upfront costs, as attorney fees will be covered through a contingency fee arrangement, thereby reducing the financial burden on affected investors and encouraging broader participation.
- Reputation Damage: The lawsuit claims that Corcept failed to disclose the inadequacy of clinical evidence when submitting its New Drug Application to the FDA, leading to investor losses upon the revelation of the truth, which may have long-term implications for the company's future financing and market trust.
See More
Corcept Therapeutics Securities Fraud Lawsuit Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by April 21, 2026, to participate in the securities fraud class action against Corcept Therapeutics (NASDAQ:CORT), which involves stock purchases made between October 31, 2024, and December 30, 2025, indicating a significant loss of investor confidence in the company's future prospects.
- FDA Rejection: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter (CRL) declining to approve its New Drug Application (NDA) for relacorilant, resulting in a 50.42% drop in stock price to $34.80 per share, highlighting the direct impact of regulatory risks on the company's market valuation.
- Clinical Development Concerns: The updated CRL revealed that the FDA had significant concerns regarding the adequacy of Corcept's clinical development program to assess relacorilant's effectiveness, suggesting that the company failed to meet regulatory expectations, which could lead to further review issues and increased investor anxiety.
- False Statements Allegations: The class action alleges that defendants made materially false and misleading statements throughout the class period, failing to disclose the FDA's concerns about the effectiveness assessment of relacorilant, leading to a misunderstanding of the company's prospects and reflecting serious deficiencies in corporate governance and transparency.
See More
Class Action Lawsuit Announced for Corcept Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, indicating potential investor losses.
- Lawsuit Background: The lawsuit alleges that Corcept made false representations regarding the efficacy of clinical trials supporting its New Drug Application, leading investors to be unaware of the significant risks associated with FDA approval.
- Compensation Mechanism: Investors joining the class action can receive compensation without any out-of-pocket fees, facilitated through a contingency fee arrangement, thus alleviating financial burdens on investors.
- Legal Counsel Recommendation: Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record to ensure that investors' rights are effectively protected in the class action process.
See More
Corcept Therapeutics Faces Class Action Lawsuit Over Misleading FDA Claims
- Lawsuit Background: Hagens Berman has filed a class action lawsuit against Corcept Therapeutics and its executives, alleging that misleading statements made between October 31, 2024, and December 30, 2025, resulted in significant investor losses.
- Concealed FDA Warnings: The lawsuit claims that Corcept misled the market by asserting its lead product was nearing approval, despite receiving multiple warnings from the FDA about inadequate clinical data prior to its NDA submission, leading to investor misconceptions about the company's prospects.
- Stock Price Plummet: On December 31, 2025, Corcept's stock price collapsed from $70.20 to $34.80 following the announcement of a Complete Response Letter from the FDA, erasing over $3.6 billion in market value, reflecting extreme market disappointment in the company's future.
- Investor Action Call: Hagens Berman urges investors who purchased Corcept stock during the class period to contact the firm by April 21, 2026, to discuss their rights and potentially serve as lead plaintiffs in the lawsuit, emphasizing the importance of protecting their interests.
See More
